| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11008577 | Journal of Clinical Lipidology | 2018 | 9 Pages |
Abstract
The HAUSER-RCT study, the largest randomized, placebo-controlled study with proprotein convertase subtilisin/kexin type 9 inhibitors being conducted in the pediatric HeFH population, aims to provide efficacy, safety, and tolerability data of evolocumab as an add-on therapy in these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Daniel MD, PhD, Gisle MD, Samuel S. MD, Ilse K. MD, Andrea MD, PhD, Christopher MD, Chen PhD, Ransi MD, Frederick J. MBBCh, PhD, Albert MD, PhD,